In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3001-3013

  Chen, Kai ^a   Wang, Ketai ^a   Kirichian, Agop M ^a   Al Aowad, Ayman F ^a   Iyer, Lakshmanan K ^b   Adelstein, S James ^a   Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' HYDROXYPHENYL) 6 IODO 4 (3H)QUINAZOLINONE I 125; ALKALINE PHOSPHATASE; AMMONIUM 2 (2' PHOSPHORYLOXYPHENYL) 6 IODO 4 (3H)QUINAZOLINONE I 125; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; COMPUTER MODEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR; X RAY CRYSTALLOGRAPHY;

ALKALINE PHOSPHATASE; ANIMALS; AUTORADIOGRAPHY; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HYDROLYSIS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, INBRED C3H; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; NEOPLASMS; PRODRUGS; QUINAZOLINONES; RATS; THERMODYNAMICS;

EID: 33846226440     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0465     Document Type: Article

References (36)

1. Kassis AI, Harapanhalli RS. Methods for tumor diagnosis and therapy. U.S. patent 09/839,779. Pending 2001.
2. Ho N, Harapanhalli RS, Dahman BA, et al. Synthesis and biologic evaluation of a radioiodinated quinazolinone derivative for enzyme-mediated insolubilization therapy. Bioconjug Chem 2002; 13:357-64.
3. Suzuki H, Iino S, Endo Y, Torii M, Miki K, Oda T. Tumor-specific alkaline phosphatase in hepatoma. Ann N Y Acad Sci 1975;259:307-20.
4. Miyayama H, Doellgast GJ, Memoli V, Gandbhir L, Fishman WH. Direct immunoperoxidase staining for Regan isoenzyme of alkaline phosphatase in human tumor tissues. Cancer 1976;38:1237-46.
5. Benham F, Cottell DC, Franks LM, Wilson PD. Alkaline phosphatase activity in human bladder tumor cell lines. J Histochem Cytochem 1977; 25:266-74.
6. Benham FJ, Povey MS, Harris H. Placental-like alkaline phosphatase in malignant and benign ovarian tumors. Clin Chim Acta 1978; 86:201-15.
7. Benham FJ, Harris H. Human cell lines expressing intestinal alkaline phosphatase. Proc Natl Acad Sci U S A 1979;76:4016-9.
8. Andrews PW, Bronson DL, Benham F, Strickland S, Knowles BB. A comparative study of eight cell lines derived from human testicular teratocarcinoma. Int J Cancer 1980;26:269-80.
9. Benham FJ, Fogh J, Harris H. Alkaline phosphatase expression in human cell lines derived from various malignancies. Int J Cancer 1981;27: 637-44.
10. Herz F. Alkaline phosphatase isozymes in cultured human cancer cells. Experientia 1985;41:1357-61.
11. Muensch HA, Maslow WC, Azama F, Bertrand M, Dewhurst P, Hartman B. Placental-like alkaline phosphatase: re-evaluation of the tumor marker with exclusion of smokers. Cancer 1986;58:1689-94.
12. Le Du MH, Stigbrand T, Taussig MJ, Ménez A, Stura EA. Crystal structure of alkaline phosphatase from human placenta at 1.8 Å resolution: implication for a substrate specificity. J Biol Chem 2001; 276:9158-65.
13. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19:1639-62.
14. Stote RH, Karplus M. Zinc binding in proteins and solution: a simple but accurate nonbonded representation. Proteins 1995;23:12-31.
15. Van Belle H. Alkaline phosphatase. I. Kinetics and inhibition by levamisole of purified isoenzymes from humans. Clin Chem 1976;22: 972-6.
16. 3-stimulated bone mineralization in the mouse. Calcif Tissue Int 1986;38:296-302.
17. Apweiler R, Attwood TK, Bairoch A, et al. The InterPro database, an integrated documentation resource for protein families, domains, and functional sites. Nucleic Acids Res 2001;29:37-40.
18. Ho DHW. Distribution of kinase and deaminase of 1-β-D-arabinofurano-sylcytosine in tissues of man and mouse. Cancer Res 1973;33:2816-20.
19. Frei E III, Teicher BA, Holden SA, Cathcart KNS, Wang Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988;48:6417-23.
20. Denny WA. Tumor-activated prodrugs - a new approach to cancer therapy. Cancer Invest 2004;22:604-19.
21. Bagshawe KD. Antibody-directed enzyme prodrug therapy. Clin Pharmacokinet 1994;27:368-76.
22. Springer CJ, Antoniw P, Bagshawe KD, Wilman DEV. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des 1991;6:467-79.
23. Melton RG, Sherwood RF. Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 1996;88:153-65.
24. Antoniw P, Springer CJ, Bagshawe KD, et al. Disposition of the prodrug 4-(bis(2-chloroethyl)amino)benzoyl-L-glutamic acid and its active parent drug in mice. Br J Cancer 1990;62:909-14.
25. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59:1417-21.
26. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187:22-36.
27. Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol 2003; 2003:48-70.
28. Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 1990; 186:133-50.
29. Jöbsis AC, de Vries GP, Meijer AEFH, Ploem JS. The immunohistochemical detection of prostatic acid phosphatase: its possibilities and limitations in tumour histochemistry. Histochem J 1981;13: 961-73.
30. Loor R, Wang MC, Valenzuela L, Chu TM. Expression of prostatic acid phosphatase in human prostate cancer. Cancer Lett 1981; 14:63-9.
31. Nadji M, Morales AR. Immunohistochemical markers for prostatic cancer. Ann N Y Acad Sci 1983;420:134-9.
32. Azumi N, Traweek ST, Battifora H. Prostatic acid phosphatase in carcinoid tumors: immunohistochemical and immunoblot studies. Am J Surg Pathol 199 1;15:785-90.
33. Ito T, Furusato M, Akiyama A, Kato H, Aizawa S. A clinical and immunohistochemical study of papillary adenocarcinoma of the prostate. Prostate 1995;26:23-7.
34. Sinha AA, Quast BJ, Wilson MJ, et al. Immunocytochemical localization of an immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5-fluoro-2′-deoxyuridine) in human prostate tumors. Anticancer Res 1998; 18:1385-92.
35. Chang SS, Reuter VE, Heston WDW, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001;57:1179-83.
36. Haughland RP, Zhang Y, Yue ST, et al. Enzymatic analysis using substrates that yield fluorescent precipitates. U.S. patent 5,316,906. 1994 May 31.